Overview

Open-label Extension Study to Assess Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis

Status:
Terminated

Trial end date:
2018-07-18

Target enrollment:

Participant gender:

Summary

The purpose of this study is to allow subjects completing study LYC-30937-2001 the opportunity to receive LYC-30937-EC 25 mg.

Phase:

Phase 2

Details

Lead Sponsor:

Lycera Corp.